Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The taxoids: same roots, different drugs

D D Von Hoff1

  • 1Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center, San Antonio 78245, USA.

Seminars in Oncology
|August 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).

Cancer chemotherapy and pharmacology·2014
Same author

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.

European journal of cancer (Oxford, England : 1990)·2012

Paclitaxel and docetaxel are taxoid anticancer drugs with unique properties. Differences in their microtubule binding and toxicity profiles guide clinical use and management strategies for various malignancies.

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Paclitaxel and docetaxel are crucial taxoid compounds for cancer treatment.
  • These drugs, derived from the Pacific yew, represent significant advancements in managing diverse malignancies.

Purpose of the Study:

  • To compare the biological and clinical differences between paclitaxel and docetaxel.
  • To elucidate the implications of these differences in drug efficacy and toxicity.

Main Methods:

  • Analysis of preclinical and clinical studies on taxoid compounds.
  • Review of data on drug-induced adverse events and management strategies.

Main Results:

  • Paclitaxel and docetaxel exhibit distinct mechanisms in microtubule stabilization and binding affinity.

Related Experiment Videos

  • Differences in toxicity profiles, including liver function impact and hypersensitivity, are noted.
  • Premedication regimens and dosage adjustments are crucial for managing docetaxel's adverse events.

    • Conclusions:

    • Despite a shared chemical origin, paclitaxel and docetaxel possess unique characteristics influencing their clinical application.
    • Understanding these differences is key to optimizing treatment outcomes and patient management.
    • Ongoing research aims to further refine taxoid-based therapies for improved cancer treatment.